Pharmaceuticals-maker Sanofi-Synthelabo formally announced plans Monday to create the world’s third-largest pharmaceutical company after making a new, “friendly” bid for the Franco-German Aventis SA ...

Sanofi Synthélabo, the French pharmaceuticals group, on Monday launched a €48.5bn ($61 billion) hostile takeover bid for Aventis, its larger Franco-German rival, in a daring move to create the ...

Drug maker Sanofi-Synthelabo ended weeks of speculation about a friendly merger with Aventis by launching a hostile $60.2-billion takeover bid Monday for its larger rival. Outlining the offer that ...

French drug maker Sanofi-Aventis SA has agreed to buy Genzyme Corp. in a sweetened all-cash $20.1 billion deal that ends months of corporate haggling and positions Sanofi at the forefront of the ...

Where there are threats of serious or irreversible damage, lack of full scientific certainty shall not be used as a reason for postponing cost-effective measures to prevent environmental degradation. ...

CARLSBAD, Calif.--(BUSINESS WIRE)-- Regulus Therapeutics Inc. and sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that they have entered into a global, strategic alliance to discover, ...

Aventis and Andrx Corp. agreed to pay $80 million to settle lawsuits that claimed the companies conspired to keep generic forms of the blood-pressure drug Cardizem CD off the U.S. market, New York ...

The French-German drug company Aventis said Monday morning that it had accepted an offer from a once-hostile bidder, Sanofi-Synthelabo, of $65.5-billion, 14 percent higher than Sanofi's original bid ...